The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Somero upbeat after strong year; Scancell in profit

Wed, 26th Jan 2022 20:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Somero Enterprises Inc - Fort Myers, Florida-based concrete levelling equipment company - Reports "strong, profitable trading" and now expects 2021 revenue, earnings before interest, tax, depreciation and amortisation, and year-end cash ahead of guidance. Expects revenue of around USD133.0 million versus guidance of USD130.0 million, adjusted Ebitda of USD48.0 million, up 83% on 2020 and ahead of guidance at USD45.0 million, and year-end cash of USD42.0 million, versus guidance of USD39.0 million. Expects 2022 will be "highly profitable year".

----------

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Reports pretax profit of GBP2.5 million for six months to October 31, swinging from loss of GBP4.4 million year-on-year. Firm gets boost from GBP7.2 million gain on substantial modification of convertible loan notes. Says firm is well-funded and strong cash position should allow it to "pursue multiple clinical programmes". "The funding received in the last financial year will also provide the company with further flexibility regarding the development plans for its existing therapies, to ensure both optimal development and commercialisation strategies can be pursued, and to limit the potential impact on the company of economic pressures caused by Covid-19," it says.

----------

Hargreaves Services PLC - Durham, England-based services to industrial and property sectors - Revenue for six months to November 30 falls to GBP76.1 million from GBP92.0 million a year ago but pretax profit jumps to GBP10.4 million from GBP1.1 million on boost from share of profit in joint ventures. Says revenue reduced as expected following exit from coal business. Interim dividend lifted to 2.8p from 2.7p. "The German joint venture continues to deliver substantial profits and our balance sheet is strong with no bank debt. The board has increased its expectations for financial performance in the current and future years materially and I look forward to reporting further progress in due course," says Chair Roger McDowell.

----------

Henderson Smaller Cos Investment Trust PLC - invests in medium and small UK companies - Net asset value total return minus 2.1% for six months to November-end, faring better than benchmark which falls 2.8%. NAV per share stands at 1,286.2p at November 30, down from 1,329.1p at May 31 but up from 1,017.4p a year ago. Maintains interim dividend at 7.0p per share. "During the six months to 30 November 2021, UK equity markets were broadly flat, although smaller companies underperformed larger stocks as investor sentiment shifted from growth-oriented companies to those with more value type characteristics," firm notes.

----------

Rockpool Acquisitions PLC - special purpose acquisition company - Reports pretax loss of GBP13,004 million for six months to end of September, widened from GBP5,887 a year ago. No revenue recorded in either period. Says continued hunt for acquisition in the period and remains confident in a transaction materialising "delay in and the anticipated termination of the transaction previously proposed with Greenview Gas". Plans to apply to UK Financial Conduct Authority to have share suspension lifted as soon as transaction with Greenview is terminated, expected to happen by March-end.

----------

Okyo Pharma Ltd - London-headquartered biotechnology company - Reports loss of GBP2.0 million for six months to September-end, widened from GBP485,960 a year ago. Total assets down to GBP4.2 million from GBP5.1 million at March 31. Firm says it needs to raise additional investment in order to meet liabilities over next 12 months. "Consequently, in the opinion of the directors there is a material uncertainty that may cause significant doubt about the group's ability to continue as a going concern. Despite this material uncertainty, the directors conclude that it is appropriate to continue to adopt the going concern basis of accounting," firm says.

----------

Chrysalis Investments Ltd - investor in technology and finance startups - Net asset value per share rises 57% to 251.96p at end of September from 160.97p a year ago. Says it achieved further diversification during the year and added five new investments, taking portfolio to 15 holdings. "The board is delighted with the performance of the investment team, to which further resource was added post year end to bolster the Finance and ESG functions. In the space of three years, the team has built a unique platform by which ordinary investors can access the opportunities available in the late-stage private market. With interest in private investing growing, I believe Chrysalis is extremely well placed to continue its development," says Chair Andrew Haining.

----------

Warehouse REIT PLC - real estate investment trust focused on warehouse assets - Has completed 12 new lettings and 10 lease renewals since October 1, with transactions completed at 11% ahead of March estimated rental value, generating GBP900,000 per year of contracted rent. Rent collection has remained strong with over 98% of rent due for the financial year ending March 31 collected. Affirms near-term intention to move to London's Main Market.

----------

Bushveld Minerals Ltd - South African vanadium producer - Reports 2021 production of 3,592 metric tonnes of vanadium, at the upper end of guidance but slightly below 2020's 3,631 mtV. Sales of 3,314 mtV in year were "impacted by challenges in international logistics channels arising from Covid-19, the unrest in South Africa and disruptions at local ports in July and August". Expects production of between 4,200 mtV and 4,400 mtV in 2022. "We look forward to the year ahead on the back of the strong foundation we have set and the production growth mostly attributable to the Kiln 3 commissioning in 2022. Production growth is key to unit cost reduction and margin expansion, as reflected in the guidance for 2022," says Chief Executive Fortune Mojapelo.

----------

Medica Group PLC - Hastings, England-based provider of medical imaging services - Shows "robust recovery" in 2021 and expects revenue for year to be GBP61.9 million, up 68% on the year before and 33% higher than 2019. "An increase in gross margin compared with 2020, together with careful control of costs during the pandemic means that underlying profit for the year is expected to be ahead of market expectations," it says. Ends year with net cash of GBP3.6 million after starting with debt of GBP3.9 million. Notes risks from new Covid variants, but is confident clients have now developed strategies to minimise hospital disruption. "Building on a successful 2021 and our recent acquisitions, we believe Medica is well positioned to take advantage of future opportunities," it says.

----------

Revolution Beauty Group PLC - AIM-listed beauty products retailer - Says sales over peak Christmas trading period up 41% year-on-year on underlying basis and retains guidance for full-year. "As we look forward, our growth in our direct to consumer business coupled with our successful retail expansion into the UK and the US provides strong momentum for the business. We look forward to updating the market with our full year results later in the year," says Chief Executive & Co-Founder Adam Minto.

----------

Dianomi PLC - London-based digital advertiser - Says revenue growth in excess of 25% in 2021, while adjusted Ebitda is seen slightly ahead of market expectations. Says year was "excellent". "Demand from both advertisers and publishers has been strong and the second six months of the year saw further new advertisers and publishers 'go live' on Dianomi's platform, as well as growth within the existing publisher and advertiser base," firm says.

----------

Restore PLC- Redhill, England-based document management and IT recycling business - Says 2021 performance was ahead of expectations after strong final quarter. Expects to report "record" levels of revenue and underlying profit . Says annualised revenue run rate has expanded to GBP255 million, up 18% on pre-pandemic levels. "Trading since the end of FY21 has followed the same positive trajectory seen in December and the board remain very confident in delivering further significant progress in 2022," company adds.

----------

Anpario PLC - Nottingham, England-based manufacturer of animal feed additives - Earnings for 2021 to be in line with current market expectations with full year sales to be not less than GBP33 million. Says operating performance strong despite "number of challenges" in global markets and supply chains due to pandemic. "We have continued to experience increased logistics and raw material price inflation, the cost of which is being passed on through sales price increases. We are seeing some encouraging signs that cost price inflation has begun to stabilise and the improving international travel situation will help our sales teams drive new business development initiatives," firm adds.

----------

Flowtech Fluidpower PLC - supplier of technical fluid power products - Expects to report 2021 revenue around GBP109.9 million, up 15% on 2020 but 3% below 2019. Expects underlying profit to be in line with board expectations. Expects to reintroduce final dividend payment for 2021. Says is satisfied with trading performance in year and encouraged by start to 2022, though adds: "Whilst demand throughout the fluid power market has continued to recover, it is clear that it will be well into 2022, if not longer, before global supply chains for fluid power product return to pre pandemic levels of both consistency and breadth of supply. Good progress against our strategic objectives continues to enhance the group's medium term prospects. However, until supply is fully recovered, the board is more cautious in the short term outlook."

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.